NDA 218808 · Neurocrine
Crenessity
Crinecerfont · Oral
NovelBreakthrough therapyPriority reviewOrphanCDER novel approval, Dec 13, 2024: To treat classic congenital adrenal hyperplasia
Last checked: Nov 20, 2026Latest source record: Dec 13, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2024
Dec 13, 2024
Approved uses
1
Original approval plus efficacy supplements
Registered trials
7
3 Phase 3, 1 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. FDA's summary: To treat classic congenital adrenal hyperplasia
Therapeutic areas: Rare and genetic disease · Kidney and urology · Endocrinology and women's health
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 13, 2024 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLabelLetterReview
3 products under this application
- CRENESSITY · CRINECERFONT 50MG · CAPSULE, ORAL · Prescription
- CRENESSITY · CRINECERFONT 100MG · CAPSULE, ORAL · Prescription
- CRENESSITY · CRINECERFONT 25MG · CAPSULE, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Crinecerfont" as an intervention, any sponsor and status, largest first.
- Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal HyperplasiaPivotal-lookingActive, not recruiting
Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
NCT04490915 · 182 participants · Start Dec 16, 2020 · Primary completion Jul 19, 2023
Drug: Crinecerfont; Placebo · For: Congenital Adrenal Hyperplasia
Sites: Los Angeles, California; San Diego, California; San Francisco, California · 70 sites in all
- Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Participants With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study)Pivotal-lookingActive, not recruiting
Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
NCT04806451 · 103 participants · Start Jun 25, 2021 · Primary completion Mar 10, 2023
Drug: Crinecerfont; Placebo · For: Congenital Adrenal Hyperplasia
Sites: Birmingham, Alabama; Los Angeles, California; Orange, California · 46 sites in all
- Study to Evaluate the Effect of Crinecerfont on Androgen Reduction and Related Outcomes in Adults With Classic Congenital Adrenal Hyperplasia (CAH)Pivotal-lookingNot yet recruiting
Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
NCT07947368 · 100 participants (planned) · Start Nov 2026 · Primary completion Jan 2028
Drug: Crinecerfont · For: Congenital Adrenal Hyperplasia
Neurocrine Switzerland GmbHNeurocrine Biosciences (NBIX)
NCT07536269 · 20 participants (planned) · Start Jul 1, 2026 · Primary completion Mar 2028
Drug: Crinecerfont · For: Congenital Adrenal Hyperplasia
Sites: San Francisco, California; Aurora, Colorado; Hartford, Connecticut · 11 sites in all
Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
NCT03525886 · 18 participants · Start Apr 10, 2018 · Primary completion Apr 7, 2020
Drug: NBI-74788 · For: CAH - Congenital Adrenal Hyperplasia
Sites: Aurora, Colorado; Indianapolis, Indiana; Ann Arbor, Michigan · 6 sites in all
Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
NCT04045145 · 8 participants · Start Dec 12, 2019 · Primary completion Jul 2, 2021
Drug: Crinecerfont · For: CAH - Congenital Adrenal Hyperplasia
Sites: San Diego, California; Aurora, Colorado; Ann Arbor, Michigan · 6 sites in all
- Pharmacokinetics, Safety and Tolerability of Crinecerfont in Participants With Congenital Adrenal Hyperplasia Who Are Less Than 2 Years OldActive, not recruiting
Neurocrine Switzerland GmbHNeurocrine Biosciences (NBIX)
NCT07187375 · 7 participants · Start Sep 30, 2025 · Primary completion Sep 6, 2029
Drug: Crinecerfont · For: Congenital Adrenal Hyperplasia
Sites: Berlin, Germany; Düsseldorf, Germany; Heidelberg, Germany
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Phase 3 Trial of Crinecerfont in Pediatric Congenital Adrenal Hyperplasia.
Sarafoglou K, Kim MS, Lodish M, et al. · N Engl J Med 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Phase 3 Trial of Crinecerfont in Adult Congenital Adrenal Hyperplasia.
Auchus RJ, Hamidi O, Pivonello R, et al. · N Engl J Med 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Crinecerfont Lowers Elevated Hormone Markers in Adults With 21-Hydroxylase Deficiency Congenital Adrenal Hyperplasia.
Auchus RJ, Sarafoglou K, Fechner PY, et al. · J Clin Endocrinol Metab 2022 · Clinical Trial, Phase II, Research Support, Non-U.S. Gov't
Sponsor: Neurocrine Biosciences
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.